Todd Berard Sells 3,000 Shares of BioLife Solutions Inc (BLFS) Stock

BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $16.96, for a total transaction of $50,880.00. Following the sale, the vice president now owns 44,074 shares in the company, valued at $747,495.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Todd Berard also recently made the following trade(s):

  • On Monday, April 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.56, for a total transaction of $52,680.00.
  • On Thursday, March 14th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.67, for a total transaction of $50,010.00.

BLFS stock traded up $0.48 during mid-day trading on Friday, hitting $18.22. 129,539 shares of the company were exchanged, compared to its average volume of 117,310. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.99 and a current ratio of 14.50. The company has a market capitalization of $342.52 million, a P/E ratio of 107.18 and a beta of 1.53. BioLife Solutions Inc has a 1-year low of $8.50 and a 1-year high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, hitting the consensus estimate of $0.03. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. The firm had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.67 million. Analysts forecast that BioLife Solutions Inc will post 0.13 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Roubaix Capital LLC acquired a new stake in shares of BioLife Solutions in the first quarter valued at approximately $809,000. Vanguard Group Inc. raised its holdings in shares of BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc. now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of BioLife Solutions by 43.1% in the third quarter. Vanguard Group Inc now owns 447,984 shares of the medical equipment provider’s stock valued at $7,839,000 after purchasing an additional 134,869 shares during the last quarter. BlackRock Inc. raised its holdings in shares of BioLife Solutions by 199.8% in the third quarter. BlackRock Inc. now owns 153,610 shares of the medical equipment provider’s stock valued at $2,688,000 after purchasing an additional 102,364 shares during the last quarter. Finally, GSA Capital Partners LLP raised its holdings in shares of BioLife Solutions by 21.1% in the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after purchasing an additional 2,400 shares during the last quarter. Institutional investors own 41.21% of the company’s stock.

Several brokerages have commented on BLFS. Zacks Investment Research upgraded shares of BioLife Solutions from a “sell” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Wednesday. Northland Securities restated a “buy” rating and set a $18.00 target price on shares of BioLife Solutions in a report on Monday, May 13th. BidaskClub upgraded shares of BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday, April 30th. Finally, ValuEngine downgraded shares of BioLife Solutions from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 27th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. BioLife Solutions currently has an average rating of “Buy” and an average price target of $18.20.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2019/05/19/todd-berard-sells-3000-shares-of-biolife-solutions-inc-blfs-stock.html.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: Why is momentum important to successful trading?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.